Mechanism of neurodegeneration mediated by clonal inflammatory microglia

Langerhans cell Histiocytosis (LCH) and Erdheim-Chester disease (ECD) are recognized as complex clonal myeloid disorders that frequently manifest with systemic inflammatory symptoms. Prior research has shown that these conditions are strongly associated with somatic mutations that activate the Mitogen-Activated Protein Kinase (MAPK) signaling pathway, leading to aberrant cellular proliferation. Patients suffering from these histiocytic neoplasms often face an increased risk of developing severe, progressive neurodegeneration that impairs cognitive and motor functions. Despite the identification of these genetic drivers, the precise mechanism by which systemic myeloid clones infiltrate or affect the central nervous system remained elusive for many years. The relationship between peripheral disease activity and the onset of neurological decline has been a subject of intense debate among neurologists and hematologists. Understanding whether the brain damage results from direct cellular invasion or secondary inflammatory signaling is essential for developing targeted therapies. This absence of evidence motivated the current investigation into the role of clonal inflammatory microglia as the primary mediators of neuronal damage.

This investigation sought to characterize the presence and distribution of PU.1-positive (PU.1+) microglia mutant clones within the brain tissues of individuals diagnosed with LCH and ECD. The researchers aimed to determine if these mutant populations were present in patients who had not yet developed overt neurological symptoms, indicating a preclinical phase of the disease. A primary objective involved mapping the specific anatomical locations of these clones to see if they clustered in particular regions like the rhombencephalon. The team also intended to quantify the extent of microgliosis and reactive astrocytosis associated with these mutant microglial populations to understand the broader inflammatory environment. By examining the correlation between clone size and the duration of disease evolution, the study established a timeline for neurodegenerative progression. Scientists also explored the developmental origins of these cells using genetic lineage tracing to see if they arose from resident brain macrophages or circulating bone marrow precursors. This research effort evaluated Colony-Stimulating Factor 1 Receptor (CSF1R) inhibition as a potential strategy to prevent neuronal loss.

The investigative team conducted detailed histological and molecular analyses on brain samples obtained from a cohort of patients with LCH and ECD, including those with and without clinical neurological signs. They utilized PU.1 as a specific marker to identify and quantify the presence of mutant microglial clones across various neuroanatomical regions. To understand the developmental trajectory of these cells, the scientists employed genetic lineage tracing techniques that could distinguish between yolk sac-derived resident macrophages and bone marrow-derived myeloid precursors. The researchers focused their topographical analysis on the grey nuclei of the rhombencephalon to investigate why this area showed a higher density of pathological changes. Statistical models were applied to correlate the size of the PU.1+ clones and the total duration of the disease with the severity of clinical symptoms. In the experimental phase, the team utilized a mouse model designed to mimic the clonal proliferation of inflammatory microglia observed in human patients. They administered a specific CSF1R-inhibitor to these murine subjects to determine if pharmacological depletion of the mutant microglia could effectively halt the progression of neuronal death.

The analysis revealed that pervasive PU.1+ microglia mutant clones were present in the brains of all LCH and ECD patients, regardless of whether they exhibited neurological symptoms. These mutant clones were consistently found in close proximity to areas of intense microgliosis, reactive astrocytosis, and significant neuronal loss. The researchers observed that the disease pathology predominated in the grey nuclei of the rhombencephalon, which they attributed to a localized proliferative advantage of the mutant microglia. Statistical analysis demonstrated a strong correlation between the presence of clinical symptoms and both a longer duration of disease evolution and a larger size of the PU.1+ clones (p=0.0003). The genetic lineage tracing data suggested that the origin of these mutant cells varied between patients, appearing to stem from either resident macrophage lineages or bone marrow precursors. In the animal model experiments, the administration of a CSF1R-inhibitor successfully depleted the population of mutant microglia within the central nervous system. This depletion directly resulted in a significant reduction in neuronal loss compared to untreated control groups.

The findings establish that clonal proliferation of inflammatory microglia (CPIM) is the fundamental driver of neurodegeneration in patients with LCH and ECD. This research characterizes the condition as a progressive neurodegenerative disease that includes a lengthy preclinical stage lasting one or more decades. The existence of this incipient disease phase suggests a significant therapeutic window during which medical intervention could potentially prevent permanent neuronal death. The study highlights that targeting the CSF1R pathway offers a promising alternative to traditional MAPK inhibitors for treating the neurological components of these myeloid disorders. By identifying and treating these clones before the onset of clinical symptoms, physicians might be able to alter the natural history of the disease. These results emphasize the importance of early screening for central nervous system involvement in all patients diagnosed with clonal myeloid conditions. The study's authors propose that future research should focus on refining these inhibitory strategies to ensure long-term neuroprotection in affected populations.